Traws Pharma, Inc. (NASDAQ: TRAW) has released its financial results for the year ending December 31, 2024, alongside significant updates to its investigational programs. The company has made ...

Traws Pharma ( ($TRAW) ) just unveiled an update. Traws Pharma, Inc. announced the appointment of Iain Dukes as the Interim Chief Executive ...

March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target ...

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE ...

Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen ...

Traws Pharma, Inc. announced promising results for ratutrelvir, a main protease inhibitor for COVID-19, suggesting it can be administered without ritonavir, potentially reducing the risk of drug ...

NEWTOWN, PA – Traws Pharma, Inc., a pharmaceutical company previously known as Onconova Therapeutics (NASDAQ:TRAW), has officially entered into an employment agreement with Iain Dukes as the company’s ...

NEWTOWN, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage ...

NEWTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage ...

NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage ...